399 Targeted VEGF Gene Therapy Enhances Indirect Bypass Efficacy in Chronic Cerebral Hypoperfusion

View at publisher Summarise with VIRAT
Authors: Ravi S. Nunna, Sabrina Genovese, Ibrahim Ahmad Bhatti, Marcus Jackson, Mahesh Thakkar, Farhan Siddiq
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Moyamoya disease (MD) is a progressive steno-occlusive cerebrovascular disorder marked by chronic cerebral hypoperfusion, often refractory to standard revascularization strategies. Indirect bypass procedures such as encephalomyosynangiosis (EMS) are limited by insufficient angiogenesis, leading to unpredictable outcomes. Gene therapy may overcome these constraints by bioengineering a pro-angiogenic environment at the graft–cortex interface. METHODS: Chronic cerebral hypoperfusion was induced in adult male Wistar rats (n = 20) via staged bilateral common carotid artery (CCA) ligation. Encephalomyosynangiosis (EMS) was performed during the second ligation by grafting the temporalis muscle to the cortical surface. The experimental group (n = 5) received intramuscular injection of AAV-VEGFA165 into the grafted temporalis muscle. Control groups included EMS with luciferase vector (AAV-fLuc, n = 5), EMS alone (n = 5), and bilateral CCA ligation without EMS (n = 5). Cognitive and neurologic function was assessed via Longa scale and novel object recognition (NOR). At 10 weeks, brains were harvested for VEGF and CD31 immunohistochemistry and ipsilateral cortical proteomic profiling using DIA-PASEF mass spectrometry. Differential expression analysis was performed with Spectronaut, and functional enrichment was conducted via STRING-db, Gene Ontology, KEGG, and Reactome to characterize VEGF-driven remodeling. RESULTS: AAV-VEGFA165 treatment significantly improved NOR performance (discrimination index p = 0.002; total exploration p = 0.041) with no differences in Longa scores, indicating enhanced recognition memory. Immunohistochemistry confirmed significant VEGF and CD31 upregulation at the EMS–cortex interface. Proteomic analysis identified 1,358 differentially expressed proteins, revealing VEGF-driven remodeling of cytoskeletal architecture, axon guidance, vesicle cycling, and metabolic reprogramming, including suppressed oxidative phosphorylation and enhanced glycolytic and lysosomal activity. Network drivers included actin-β, SDHA, and VAMP2, supporting synaptic and vascular plasticity. CONCLUSIONS: AAV-mediated VEGFA165 gene therapy enhances the efficacy of encephalomyosynangiosis in a rat model of MD, driving improved cognitive outcomes, sustained angiogenesis, and proteomic remodeling across vascular, synaptic, and metabolic pathways. These findings support a novel gene-augmented surgical strategy for moyamoya disease and lay the groundwork for future translational research.

Fields of Study & Subjects

Moyamoya disease diagnosis and treatment Neurological Disease Mechanisms and Treatments Barrier Structure and Function Studies

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
111–112
Publication date
26 March 2026
Language
EN